New PET scan hunts down hidden prostate cancer for precision radiation

NCT ID NCT03160794

Completed Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new type of PET/MRI scan that uses a special tracer to find small spots of prostate cancer that standard scans miss. Men with a rising PSA after prostate surgery and radiation received targeted radiation to those spots. The goal was to see if this approach can detect and treat early cancer spread, potentially controlling the disease without immediate hormone therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]DCFPyL (a radioactive tracer for PET scans) and stereotactic ablative radiotherapy (SABR)
What this could lead to: If successful, this approach could allow earlier detection and targeted treatment of prostate cancer that has spread, potentially delaying the need for hormone therapy and improving disease control.
What could go wrong: This is a Phase 2 study with 150 participants, so results are preliminary. The imaging may not find all cancer spots, and radiation could miss some targets or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST PROSTATECTOMY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST PROSTATECTOMY

Contacts and locations

Locations

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.